EXPANDed studies analysis, presented by R. Estevez-Loureiro
TR reduction in patients treated for MR with MitraClip™ TEER (without additional tricuspid intervention) in the EXPANDed studies was associated with significant quality-of-life improvement and lower mortality at 1 year. MitraClip™ TEER is not indicated for the treatment of TR nor TR patients.
LEARN MORE:
Related Resources
bRIGHT 2-year real-world outcomes
TRILUMINATE Pivotal - 2-year update EuroPCR 25
Poster: Primary MR in the Very Elderly
PCR LV 2021: Navitor™ 30-day outcomes
Epic Mitral – 10-Year Clinical Outcomes
ESOC presentation: PFO closure in patients > 60 Years
EuroPCR 2022: TAVI 1yr outcomes
Navitor Valve in small aortic annuli
TRENDING TOPICS
TRILUMINATE Pivotal - 2-year update EuroPCR 25
Poster: Primary MR in the Very Elderly
bRIGHT 2-year real-world outcomes
